Quadrant Capital Group’s NGM Biopharmaceuticals, Inc. Common Stock NGM Stock Holding History

Quadrant Capital Group’s Portfolio NGM Stock Details NGM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-106	Closed	-$275	–	2782
2023 Q2	$275	Buy	106 +26	+33%	+$93	﹤0.01%	2636
2023 Q1	$327	Buy	+80	New	+$370	﹤0.01%	2643
2022 Q3	–	Sell	-22	Closed	–	–	2851
2022 Q2	$0	Buy	+22	New	+$305	﹤0.01%	2807
2022 Q1	–	Sell	-21	Closed	–	–	2740
2021 Q4	$0	Sell	21 -4	-16%	-$77	﹤0.01%	2746
2021 Q3	$1K	Buy	+25	New	+$550	﹤0.01%	2431
2021 Q2	–	Sell	-27	Closed	-$1K	–	2611
2021 Q1	$1K	Buy	+27	New	+$756	﹤0.01%	2331
2020 Q2	–	Sell	-42	Closed	-$1K	–	2442
2020 Q1	$1K	Buy	+42	New	+$686	﹤0.01%	2070

Other funds holding NGM

Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

StepStone Group La Jolla, California $207M AUM 12.33% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Quadrant Capital Group's NGM Position: Q3 2023 in Review

Quadrant Capital Group sold out of NGM Biopharmaceuticals, Inc. Common Stock (NGM) in Q3 2023, closing a stake of 106 shares — an estimated $275 sold.

Quadrant Capital Group first reported a position in NGM in Q1 2020 and held it in 7 quarters. The position peaked at $1K in Q3 2021. 94 funds tracked by Wall St. Rank hold NGM as of Q3 2023.

Quadrant Capital Group reported no remaining NGM Biopharmaceuticals, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
Quadrant Capital Group sold 106 NGM Biopharmaceuticals, Inc. Common Stock shares in Q3 2023, an estimated $275.
Quadrant Capital Group first reported a position in NGM Biopharmaceuticals, Inc. Common Stock in Q1 2020 and held it in 7 quarters.
Quadrant Capital Group's NGM Biopharmaceuticals, Inc. Common Stock position peaked at $1K in Q3 2021.
94 funds tracked by Wall St. Rank held NGM Biopharmaceuticals, Inc. Common Stock as of Q3 2023.

Based on Quadrant Capital Group's 13F filing for Q3 2023, filed 14 Nov 2023.